Status: Recruiting
Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy
This is a Phase IIA, randomized, double blind, placebo controlled, multicenter study designed to assess the safety, feasibility, and efficacy of umbilical cord derived mesenchymal stromal cells (UC MSCs, stem cells), administered intravenously (IV) as a single dose or repeated doses, in patients with ischemic cardiomyopathy (ICM).
Participants needed: 60
Trial details
Phase: Phase 2Age: 21-85Biological sex: AllType: InterventionalSponsor: Roberto BolliUpdated: May 13, 2026Locations: 3
Eligibility criteria
Be ≥ 21 and ≤ 85 years of age. [+6]
Indication for standard of care surgery (including valve surgery, placement of l... [+28]